Omada Health Q3 2026: Profitability Inflects as Revenue Climbs 34%

What happened

Omada Health reported Q3 2026 revenue of $91 million, up 34% year over year, with gross margin expanding to 76% GAAP from 66% a year earlier. The company swung to net income of $7 million and adjusted EBITDA of $12 million, a sharp improvement from the prior-year loss and $2 million EBITDA, respectively. Total members reached 1.1 million, a 36% increase from a year ago, though growth slowed from the 55% pace recorded at end-2025. Management raised its full-year 2026 outlook, and cash rose to $243 million, strengthening the balance sheet. These results begin to validate the operating leverage thesis, but the deceleration in member growth warrants monitoring.

Implication

Investors should watch whether margin gains are sustainable and if member growth stabilizes; the company's dependence on key partners and the unproven GLP-1 initiative remain key risks. Sustained profitability could reduce the discount applied to the shares, but valuation still hinges on continued execution.

Thesis delta

The original thesis emphasized hyper-growth (>40% member growth) and anticipated only breakeven adjusted EBITDA. Q3 2026 shows member growth has moderated to 36% but profitability exceeded expectations, with adjusted EBITDA of $12 million. This shifts the investment case from a pure growth story to a profitable growth story, reducing some speculative risk but also lowering the growth premium.